title: Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
abstract: Many patients who require allogeneic hematopoietic stem cell transplantation (allo-HSCT) lack a human leukocyte antigen (HLA)-matched donor. Here, we report a protocol for haploidentical allo-HSCT that combines granulocyte-colony stimulating factor primed bone marrow (G-BM) and peripheral blood stem cells (PBSC) without in vitro T-cell depletion (TCD). In this study, 171 patients, including 86 in high-risk group, underwent transplantation from haploidentical family donors. All patients achieved sustained, full donor chimerism. One hundred and eleven patients were alive in remission at a median of 682 (253-1502) days. The cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) was 23% and that of extensive chronic GVHD, 47%; these were not influenced by HLA disparity. Patients younger than 15 years had less grade III-IV acute GVHD than older patients (P=0.044). The 2-year probability of relapse was 12% for standard-risk disease and 39% for high-risk disease. The 2-year probability of leukemia-free survival (LFS) was 68% for standard-risk patients and 42% for high-risk patients (P=0.0009). Grade III-IV acute GVHD was associated with better LFS (P=0.0017). The results require confirmation and show that G-BM combined with PBSC from haploidentical family donors, without in vitro TCD, may be used as a good source of stem cells for allo-HSCT.
authors.affiliation: Peking University Institute of Hematology, People's Hospital, Beijing, PRC. xjhrm@medmail.com.cn
authors.forename: X-J
authors.initials: XJ
authors.lastname: Huang
authors.forename: D-H
authors.initials: DH
authors.lastname: Liu
authors.forename: K-Y
authors.initials: KY
authors.lastname: Liu
authors.forename: L-P
authors.initials: LP
authors.lastname: Xu
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: W
authors.initials: W
authors.lastname: Han
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chen
authors.forename: J-Z
authors.initials: JZ
authors.lastname: Wang
authors.forename: Z-Y
authors.initials: ZY
authors.lastname: Gao
authors.forename: Y-C
authors.initials: YC
authors.lastname: Zhang
authors.forename: Q
authors.initials: Q
authors.lastname: Jiang
authors.forename: H-X
authors.initials: HX
authors.lastname: Shi
authors.forename: D-P
authors.initials: DP
authors.lastname: Lu
mesh_terms: D000293:Adolescent; D000328:Adult; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006239:Haplotypes; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes; D013997:Time Factors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor